What is the recommended initial guideline‑directed therapy for a patient with newly reduced heart failure with reduced ejection fraction (HFrEF) present on admission?

Initial Guideline-Directed Therapy for Newly Reduced HFrEF Present on Admission

Start quadruple therapy immediately upon diagnosis with ACE-I (or ARNI), beta-blocker, MRA, and SGLT2 inhibitor, along with diuretics if congestion is present—this approach reduces mortality and hospitalization most effectively when initiated rapidly and simultaneously rather than sequentially. 1, 2

Core Pharmacological Foundation

The 2022 ACC/AHA/HFSA guidelines and 2016 ESC guidelines establish four foundational drug classes (Class I recommendations) that should be initiated as soon as possible:

The "Fantastic Four" for HFrEF:

1. ACE-Inhibitor or ARNI (Class I, Level A)

   • Start ACE-I immediately (e.g., enalapril 2.5 mg twice daily, lisinopril 2.5-5 mg daily) 1, 3
   • ARNI (sacubitril/valsartan) can replace ACE-I and is preferred if patient remains symptomatic, though recent evidence supports de novo initiation in appropriate candidates 4, 2
   • Starting dose: sacubitril/valsartan 24/26-49/51 mg twice daily 4

2. Beta-Blocker (Class I, Level A)

   • Use only evidence-based agents: bisoprolol, carvedilol, or metoprolol succinate 1, 3
   • Start carvedilol 3.125 mg twice daily, bisoprolol 1.25 mg daily, or metoprolol succinate 12.5-25 mg daily 4
   • Initiate even in acute setting once hemodynamically stable

3. Mineralocorticoid Receptor Antagonist (MRA) (Class I, Level A)

   • Spironolactone 12.5-25 mg daily or eplerenone 25 mg daily 1, 4
   • Check potassium and renal function but do not delay initiation unnecessarily

4. SGLT2 Inhibitor (Class I, Level A per 2022 guidelines)

   • Dapagliflozin 10 mg daily or empagliflozin 10 mg daily 4, 2
   • Benefits independent of diabetes status
   • Can be started in-hospital during acute decompensation 2, 5

Additional Essential Therapy:

Diuretics (Class I, Level B)

• Loop diuretics for any signs/symptoms of congestion 1, 3
• Furosemide 20-40 mg once or twice daily, bumetanide 0.5-1.0 mg, or torsemide 10-20 mg 3
• Titrate to euvolemia, then maintain lowest effective dose

Implementation Strategy

Timing and Sequencing:

Initiate all four foundational therapies simultaneously or in rapid sequence within days, not weeks or months. 6, 7, 8

• Recent real-world data from TITRATE-HF shows 46% of patients achieved quadruple therapy by 6 weeks, with 50% prescribed it at some point within 6 weeks 6
• The 2023 ESC update now includes Class IB recommendation for rapid administration and prompt titration of all four drugs after HF decompensation 5
• Most titrations occur in first 60 days after diagnosis, then fade—emphasizing need for aggressive early optimization 6

Practical Initiation Algorithm:

Day 1-3 (In-Hospital or Initial Presentation):

• Start diuretics immediately if congestion present
• Initiate SGLT2 inhibitor (no titration needed—full dose from start)
• Begin ACE-I at low dose once blood pressure stable (SBP >90-100 mmHg)
• Start beta-blocker at low dose once euvolemic and hemodynamically stable

Day 3-7:

• Add MRA once potassium <5.0 mEq/L and eGFR >30 mL/min
• Begin uptitration of ACE-I and beta-blocker if tolerated

Weeks 2-12:

• Aggressive uptitration every 1-2 weeks toward target doses
• Target doses: enalapril 10-20 mg twice daily, carvedilol 25-50 mg twice daily, spironolactone 25-50 mg daily 4
• Only 1.3% achieve target doses for all four classes by 6 months in real-world practice, but higher doses correlate with better outcomes 6

Critical Caveats and Pitfalls

Common Barriers to Avoid:

Physician acceptance of suboptimal doses is a major problem—accounting for more cases of undertitration than actual side effects (20-37% due to side effects vs. larger proportion from physician inertia) 6

Discontinuation rates are relatively low (9-13% across drug classes) and primarily due to side effects 6. Crucially, rechallenge is successful in >83% of patients who initially discontinue 6—so always attempt reintroduction after temporary discontinuation.

Specific Contraindications to Monitor:

• Avoid diltiazem or verapamil (Class III, Level C)—they increase HF worsening and hospitalization 1
• Do not combine ACE-I + ARB + MRA (Class III, Level C)—excessive risk of renal dysfunction and hyperkalemia 1
• Hypotension: If SBP <90 mmHg, prioritize beta-blocker and SGLT2i over ACE-I/ARNI initially
• Hyperkalemia: Temporary MRA hold acceptable, but optimize with dietary counseling and potassium binders rather than permanent discontinuation
• Renal dysfunction: MRA can be used with eGFR >30; ACE-I/ARNI require monitoring but not absolute contraindication until eGFR <30

Special Populations:

De novo HFrEF patients (newly diagnosed, not previously on therapy) represent approximately 50% of HFrEF admissions 6 and benefit equally from aggressive quadruple therapy initiation.

Post-MI patients should receive ACE-I and beta-blocker immediately (Class I, Level A for prevention) 1, with MRA added if LVEF <40% and HF symptoms or diabetes present 9.

Monitoring and Follow-Up

• Frequent follow-up essential: Weekly to biweekly visits during first 2-3 months for dose titration 4
• Check electrolytes and renal function 1-2 weeks after each MRA or ACE-I/ARNI dose change
• Blood pressure and heart rate monitoring with each beta-blocker adjustment
• Most drug titrations should occur within first 60 days—after this window, optimization rates drop dramatically 6

Evidence Strength

The recommendations for ACE-I, beta-blocker, and MRA carry Level A evidence from multiple landmark trials demonstrating mortality reduction 1, 3. SGLT2 inhibitors now have Class I, Level A evidence from DAPA-HF and EMPEROR-Reduced trials 4, 2. The strategy of rapid, simultaneous initiation is supported by Class IB recommendation in 2023 ESC updates 5 and real-world feasibility data from 2025 6, 7.

The key paradigm shift is moving from sequential, cautious initiation over months to aggressive, simultaneous initiation within days to weeks—this approach maximizes the substantial absolute risk reduction these therapies provide when used together.